Related Experiment Video
Updated: May 24, 2025

10:37
Induction and Analysis of Epithelial to Mesenchymal Transition
Published on: August 27, 2013
35.7K
Illuminating a Dark Kinase in the Mesenchymal Cancer Cell State
1Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
Cancer Discovery
|March 3, 2025
Summary
Protein kinase N2 (PKN2) drives cancer cell survival and drug resistance by activating YAP/TAZ. Targeting PKN2 may eliminate drug-tolerant cancer cells when combined with existing therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Mesenchymal cancer cells exhibit enhanced survival and drug resistance.
- YAP/TAZ signaling pathways are implicated in cancer progression and therapeutic resistance.
Purpose of the Study:
- To identify key molecular drivers of mesenchymal cancer cell survival and drug resistance.
- To investigate the role of PKN2 in YAP/TAZ activation and its impact on cancer cell persistence.
Main Methods:
- Utilized molecular biology techniques to study protein kinase N2 (PKN2) function.
- Investigated the interplay between PKN2, YAP/TAZ, and cancer cell drug resistance.
- Assessed the therapeutic potential of targeting PKN2 in preclinical cancer models.
Main Results:
- PKN2 was identified as a critical factor promoting mesenchymal cancer cell survival.
- PKN2 activation of YAP/TAZ signaling contributes significantly to drug tolerance.
- Targeting PKN2 demonstrated efficacy in eliminating drug-tolerant persister cells.
Conclusions:
- PKN2 is a key regulator of mesenchymal cancer cell persistence and drug resistance via YAP/TAZ.
- Combination therapy targeting PKN2 with first-line treatments presents a promising strategy to overcome drug resistance.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
MAPK Signaling Cascades
5.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.1K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Amplifying Signals via Enzymatic Cascade
8.2K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K

